Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Nurix Therapeutics (NRIX) Operating Expenses: 2019-2025

Historic Operating Expenses for Nurix Therapeutics (NRIX) over the last 6 years, with Aug 2025 value amounting to $99.3 million.

  • Nurix Therapeutics' Operating Expenses rose 47.74% to $99.3 million in Q3 2025 from the same period last year, while for Aug 2025 it was $350.9 million, marking a year-over-year increase of 40.29%. This contributed to the annual value of $267.6 million for FY2024, which is 15.31% up from last year.
  • According to the latest figures from Q3 2025, Nurix Therapeutics' Operating Expenses is $99.3 million, which was up 7.47% from $92.4 million recorded in Q2 2025.
  • Nurix Therapeutics' 5-year Operating Expenses high stood at $99.3 million for Q3 2025, and its period low was $29.5 million during Q1 2021.
  • Moreover, its 3-year median value for Operating Expenses was $61.8 million (2024), whereas its average is $70.2 million.
  • Data for Nurix Therapeutics' Operating Expenses shows a peak YoY skyrocketed of 92.42% (in 2021) over the last 5 years.
  • Nurix Therapeutics' Operating Expenses (Quarterly) stood at $45.3 million in 2021, then rose by 22.32% to $55.5 million in 2022, then grew by 9.05% to $60.5 million in 2023, then climbed by 28.84% to $77.9 million in 2024, then soared by 47.74% to $99.3 million in 2025.
  • Its Operating Expenses was $99.3 million in Q3 2025, compared to $92.4 million in Q2 2025 and $81.3 million in Q1 2025.